FDA
-
-
-
-
-
-
-
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
-
-
-
-
-
-
-
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025
-
-
-
-
-
-
-
Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates
-
-
-
-
-
-
-
Windtree Therapeutics, Inc. (WINT) Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure
-
-
-
-
-
-
-
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors
-
-
-
-
-
-
-
Windtree Therapeutics, Inc. (WINT) Announces Leadership Transition Plan
-
-
-
-
-
-
-
Windtree (WINT) Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

